0001415889-21-005559.txt : 20211129 0001415889-21-005559.hdr.sgml : 20211129 20211129212528 ACCESSION NUMBER: 0001415889-21-005559 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20211118 FILED AS OF DATE: 20211129 DATE AS OF CHANGE: 20211129 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Jones Erika CENTRAL INDEX KEY: 0001895913 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39200 FILM NUMBER: 211458141 MAIL ADDRESS: STREET 1: C/O BLACK DIAMOND THERAPEUTICS, INC. STREET 2: ONE MAIN STREET, 10TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Black Diamond Therapeutics, Inc. CENTRAL INDEX KEY: 0001701541 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE MAIN STREET, 10TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-417-5868 MAIL ADDRESS: STREET 1: ONE MAIN STREET, 10TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Aset Therapeutics, Inc. DATE OF NAME CHANGE: 20170321 3 1 form3-11292021_061117.xml X0206 3 2021-11-18 0 0001701541 Black Diamond Therapeutics, Inc. BDTX 0001895913 Jones Erika C/O BLACK DIAMOND THERAPEUTICS, INC. ONE MAIN STREET, 10TH FLOOR CAMBRIDGE MA 02142 false true false false See Remarks Stock Option (Right to Buy) 10.86 2029-12-04 Common Stock 25502 D Stock Option (Right to Buy) 19 2030-01-28 Common Stock 10000 D Stock Option (Right to Buy) 24.84 2031-03-07 Common Stock 10800 D Stock Option (Right to Buy) 7.73 2031-10-17 Common Stock 4500 D Stock Option (Right to Buy) 7.62 2031-11-15 Common Stock 4500 D 25% of the shares subject to this option vested and became exercisable on October 28, 2020, with the reminder vesting in 36 equal monthly installments thereafter. 25% of the shares subject to this option vested and became exercisable on February 3, 2021, with the remainder vesting in 36 equal monthly installments thereafter. 25% of the shares subject to this option shall vest and become exercisable on March 8, 2022, with the remainder vesting in 36 equal monthly installments thereafter. The shares subject to this option shall vest and become exercisable in two equal annual installments, with the first installment vesting on October 18, 2022. The shares subject to this option shall vest and become exercisable in two equal annual installments, with the first installment vesting on November 16, 2022. Officer Title: Vice President, Finance and Corporate Controller /s/ Brent Hatzis-Schoch, Attorney-in-Fact 2021-11-29 EX-24 2 ex24-11292021_061118.htm ex24-11292021_061118.htm


POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints each of Brent Hatzis-Schoch, Marishka DeToy and Karin Yoo, signing singly, the undersigned’s true and lawful attorney-in-fact to:

(1)

execute for and on behalf of the undersigned, in the undersigned’s capacity as an officer and/or director of Black Diamond Therapeutics, Inc., a Delaware corporation (the “Company”), (i) Form ID, including any attached documents, to effect the assignment of codes to the undersigned to be used in the transmission of information to the United States Securities and Exchange Commission using the EDGAR System, (ii) Forms 3, 4 and 5, (iii) Schedule 13D, (iv) Schedule 13G and (v) amendments of each thereof, in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder;

(2)

do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5, Schedule 13D. Schedule 13G or any amendments thereto and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

(3)

take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with Section 16 or Regulation 13D-G of the Securities Exchange Act of 1934, as amended. The undersigned hereby agrees to indemnify the attorney-in-fact and the Company from and against any demand, damage, loss, cost or expense arising from any false or misleading information provided by the undersigned to the attorney-in-fact.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.  This Power of Attorney may be filed with the United States Securities and Exchange Commission as a confirming statement of the authority granted herein. This Power of Attorney supersedes any prior power of attorney in connection with the undersigned’s capacity as an officer and/or director of the Company.  This Power of Attorney shall expire as to any individual attorney-in-fact if such attorney-in-fact ceases to be an executive officer of the Company.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of November 19, 2021.



/s/ Erika Jones


Signature




Erika Jones


Print Name